ストックスクリーナーアプリを入手
192.86
0.05%
0.10
アフターアワーズ：
193.05
0.19
+0.10%
Revolution Medicines Inc (RVMD) 最新ニュース
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Revolution Medicines director Lorence Kim sells $3.58m in stock - investing.com
Revolution Medicines Director Lorence H. Kim Sells 14,090 Shares via Revocable Trust Under 10b5-1 Plan - Kalkine Media
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More. - Barron's
RVMD - Finviz
Morgan Stanley Initiates Overweight on RVMD, Highlighting RAS Pi - GuruFocus
Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise - Seeking Alpha
RVMD Initiated Coverage by Morgan Stanley -- Rating Set to Overw - GuruFocus
RVMD Maintained by Stifel -- Price Target Raised to $230 - GuruFocus
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - The Manila Times
Revolution Medicines, Inc. (RVMD) Stock Analysis: Discovering the 19.26% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval - finance.yahoo.com
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal - finance.yahoo.com
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough? - finance.yahoo.com
Revolution Medicines Got Its Breakthrough—What Moves It Next? - MarketBeat
Revolution’s Rasonque Shows Promise In Lung Cancer - insights.citeline.com
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today - Benzinga
Revolution Medicines(RVMD.US) Director Sells US$11.38 Million in Common Stock - Moomoo
RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM - GuruFocus
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer - The Manila Times
Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC - Quiver Quantitative
An experimental lung cancer drug held disease in check for 89% of patients in one group. - Stock Titan
Revolution Medicines (RVMD) insider sale under preset trading plan - stocktitan.net
Challenging Convention to Solve the Hardest Problems in Medicine – Revolution Medicines - Oncodaily
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals - BioSpace
Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines: The biotech that went all-in on RAS - Fierce Pharma
Revolution Medicines Enters Lease Agreements for New Headquarters in Redwood City - marketscreener.com
What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders - webull.com
New pancreatic cancer pill priced at $480,000 per year - KTLA
Revolution Medicines (NASDAQ: RVMD) trust moves to sell 73,090 shares - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring a Biotech Giant with 18.87% Potential Upside - DirectorsTalk Interviews
Revolution’s newly approved drug doubles pancreatic cancer survival time - Mugglehead Investment Magazine
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions - Seeking Alpha
StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy - Genetic Engineering and Biotechnology News
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer - TradingView
Revolution Medicines (RVMD) Falls as Investors Appear to Take Profits After FDA Approval - Quiver Quantitative
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug - Benzinga
Revolution Medicines stock hits all-time high at 220.8 USD - Investing.com
How Investors Are Reacting To Revolution Medicines (RVMD) First-in-Class RASONQUE Approval In Pancreatic Cancer - Yahoo Finance
Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports - marketscreener.com
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - Barchart.com
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - Yahoo! Finance Canada
Revolution Medicines (RVMD) Gains FDA Approval for Rasonque, Sha - GuruFocus
US FDA approves Revolution Medicines' pancreatic cancer drug - marketscreener.com
Opinion | A Pancreatic Cancer Revolution - WSJ
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? - The Motley Fool
New lease on life-sciences? Biotech takes 700K sf at former Google campus in Redwood City - The Real Deal
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus - The Business Journals
Revolution Medicines (NASDAQ: RVMD) trust plans 3,000-share Rule 144 sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade - Stock Titan
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale - Stock Titan
RVMD Maintained by Bernstein -- Price Target Raised to $179 - GuruFocus
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151 - Bitget
Revolution Medicines (NASDAQ: RVMD) trust to sell 3,000 shares under Rule 144 - Stock Titan
0.66%
1.97%
大文字化:
|
ボリューム (24 時間):